Inside the Parasite’s Splicing Machine: Cryo-EM Captures Trans-Splicing in Action

In nearly all eukaryotes, the messenger RNAs that carry genetic instructions must be edited before they can be translated into proteins, a task entrusted to the spliceosome, a giant ribonucleoprotein machine that removes introns from within individual transcripts. Trypanosomatid parasites, the agents of sleeping sickness, Chagas disease, and leishmaniasis, follow a strikingly different logic: in these organisms, conventional splicing is confined to just two genes, whereas virtually every mRNA receives the same short leader sequence, borrowed from a separate RNA molecule through a process known as spliced leader trans-splicing. Although this mechanism has been known for decades, its structural basis had remained elusive until researchers at The Rockefeller University and the University of Liège elucidated it in a study published on September 23, 2026, in Nature Communications.

Purifying the machinery directly from nuclear extracts of Leishmania tarentolae, the team used cryo-electron microscopy to resolve two consecutive stages of the second catalytic step, one poised for exon ligation and one immediately after it, at 2.7 and 2.8 Å, revealing an assembly of about 3.2 megadaltons built from four small nuclear RNAs and 68 proteins. Importantly, the structures disclose an extensively rewired architecture: unlike its human counterpart, the parasite machine retains the U6 LSm ring after activation, lacks intron-stabilizing factors such as RBM22 and AQR, and keeps the helicase PRP22 restrained through parasite-specific contacts, an inhibitory effect the authors confirmed biochemically, since removing its N-terminal region roughly tripled ATP turnover.

The therapeutic relevance lies precisely in these differences, because parasite-specific interfaces within an essential machine are, in principle, ideal starting points for selective drugs that would spare human splicing. Unfortunately, several caveats temper this enthusiasm: L. tarentolae infects lizards rather than humans, the work is structural and biochemical without genetic validation of individual factors, the authors do not explicitly address drug targeting, and the heterogeneity of endogenous RNA substrates limits the interpretation of some regions.

Several questions therefore remain open, including whether the LSm ring is eventually released, how the parasite recognizes its degenerate branch points, and whether the unusual ADP-bound state of the exon junction complex is a general or species-specific feature. Each represents an invitation to further research, ideally in pathogenic species, where these structural blueprints could guide the rational design of a new generation of antiparasitic therapies.